Point-Counterpoint: Should serum β-D- glucan testing be used for the diagnosis of Pneumocystis jiroveci pneumonia?
Despite the wide spread use of prophylactic antibiotics in high-risk individuals, Pneumocystis jiroveci remains an important cause of pneumonia in immunocompromised patients. During the peak of the acquired immunodeficiency disease (AIDS) epidemic many hospitals and outpatient clinics were very proficient at collecting induced sputum specimens for the diagnosis of Pneumocystis jiroveci pneumonia (PJP). With the dramatic reduction in the occurrence PJP in the current era of highly effective antiretroviral therapy, many centers no longer collect induced sputum samples. Thus, the diagnosis of PJP requires bronchoalveolar lavage specimens (BALs) or a decision to treat the patient empirically without a definitive diagnosis. Sputum or BAL specimens are tested for P. jiroveci using special stains or molecular assays, which require highly trained staff that may not be available with a rapid turn-around time. Given the invasive nature of collecting BAL specimens and the expertise needed for interpreting PJP test results, there is interest in using serum 1, 3 β-D-Glucan (BDG) testing for the diagnosis of PJP. In this point-counterpoint, Drs. Luis Ostrosky and Gabriela Corsi Vasquez will discuss the pro view of using BDG testing for the diagnosis of PJP while Drs. Paul Sax and Edward Pilkington will present the con view of using BDG for diagnosis of PJP.